The Bet NeoGenomics Holders Made Before An 80% Jump

Medicare’s decision to cover NeoGenomics’ RaDaR ST test for immunotherapy monitoring put a very specific clinical service in the spotlight, and it arrived alongside fresh quarterly results that showed revenue of US$201.656 million and a swing from a loss to a profit. For NeoGenomics shareholders, the return over the past year was 79.7%, including dividends. If you were weighing a purchase back on 2025-10-09, what exactly would you have needed to believe about this oncology diagnostics business?

The move put NeoGenomics in the middle of this trade. Scan 33 healthcare AI stocks for other companies exposed to it.

The Two NeoGenomics Stories Investors Had To Weigh

The shares cost US$8.96 at the start of the period, and NeoGenomics sat between two very different but plausible stories about where its oncology testing franchise might go next.

On the optimistic side, one narrative saw a Fair Value of US$9.78, a price implied by beliefs that new liquid biopsy and NGS products like PanTracer would help revenue grow 9.0% a year and lift profit margins toward 5.4% with a future P/E of 32.4x.

The more cautious view pointed to a Fair Value of US$6.5 and focused on risks that underused pharma services capacity, execution issues around product launches, and 8.5% assumed annual revenue growth might not be enough to offset legal and competitive pressure, even if margins eventually reached 5.4% on a future P/E of 21.8x.

What The Results Changed For The NeoGenomics Story

Medicare coverage for NeoGenomics’ RaDaR ST immunotherapy monitoring and the launch of the FDA approved PTEN IHC companion test clearly leaned toward the optimistic case that assumed new products would support oncology testing demand. A separate court win that invalidated Natera patents supported that thread. The wider history of pharma services weakness and ongoing legal and regulatory work kept the cautious narrative alive. Overall, the evidence cut both ways.

The hinge assumption here was not just test launches, but their translation into sustainable revenue and margin progress. When you assess another diagnostics business, track whether new assays and regulatory wins show up in reported sales and net margin rather than only in press releases.

What NeoGenomics’ Higher Narrative Is Asking You To Pay For Now

NeoGenomics trades at US$16.35 today, and the selected Narrative’s Fair Value figure sits above that level rather than below it. That view leans on a story in which oncology testing volumes, newer liquid biopsy offerings, and digital tooling support a sturdier earnings model.

The central question for a buyer now is whether PanTracer, RaDaR ST, and the wider test menu can keep driving mix, pricing, and lab efficiency enough to justify the Narrative’s higher number. That means deciding if sustained take up and reimbursement for these assays really holds.

"Launch of new liquid biopsy products and expanding test offerings position the company to capture market share and benefit from growth in oncology diagnostics demand. Investments in digital capabilities and strategic partnerships drive operational efficiency, support higher margins, and set up sustained earnings momentum."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Find Your Own Contrarian Opportunity

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

• Company 1 - 41% below our estimate - targets specialty deposit niches while relaunching a payments platform and expanding digital infrastructure.
• Company 2 - 43% below our estimate - scales a large infrastructure backlog as labor constraints and technology upgrades reshape project delivery.
• Company 3 - 42% below our estimate - shifts manufacturing capacity toward AI data center hardware while divesting cloud and power units.

That is three of the list. See every one of the 29 undervalued companies on it →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com